{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:13:50Z","timestamp":1791573230202,"version":"4.3.4"},"reference-count":44,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Recently, a new type of antibody-drug conjugate, trastuzumab-deruxtecan (T-DXd), has been approved for the treatment of metastatic breast cancer with low level of human epidermal growth factor receptor 2 (HER2) gene expression. Thereby, eligibility relies on an accurate diagnosis of HER2-low status defined by immunohistochemistry IHC 1+\/2+ with no gene amplification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess pathologists\u2019 accuracy and training efficacy in the diagnosis of HER2-low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Agreement rates of HER2-low scoring in breast cancer tissue were assessed between expert consensus and real-world pathologists (n = 77 from 14 countries) before and after a specific 4-hour training program for HER2-low detection. Two assays were evaluated, the Ventana Pathway 4B5 CDx and the Dako HercepTest (polyclonal). Concordance of the pathologists with consensus score and efficacy of training were measured by Cohen \u03ba, overall rater agreement, and receiver operating characteristic (ROC) curve statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>In the Ventana 4B5 HER2-low category, baseline agreement rates were &amp;gt;80% but &amp;lt;90%. Negative percentage agreement was improved from 80.6% to 91.1% by training. In the HER2-0 category, positive percentage agreement (74.6%) was the only parameter below the 80% benchmark but was significantly improved to 89.2% after training. Training efficacy was confirmed by ROC curve analysis, which shows improvement for the identification of HER2-0 and HER2-low cases. Finally, in-depth examination of cases with discordant HER2 status disclosed specific issues of HER2-low underscoring and overscoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>The ability of pathologists to achieve acceptable diagnostic accuracy in identifying patients with HER2-low breast cancer could be enhanced by short-term training. Potential routes to improve the quality of HER2-low scoring in clinical practice have been identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0052-oa","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T20:01:19Z","timestamp":1723060879000},"page":"431-438","source":"Crossref","is-referenced-by-count":31,"title":["Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer"],"prefix":"10.5858","volume":"149","author":[{"given":"Josef","family":"R\u00fcschoff","sequence":"first","affiliation":[{"name":"From the Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany (R\u00fcschoff, Penner, Baenfer, Schildhaus)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Penner","sequence":"additional","affiliation":[{"name":"From the Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany (R\u00fcschoff, Penner, Baenfer, Schildhaus)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian O.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Translational Medical Sciences, School of Medicine, The University of Nottingham, Department of Histopathology, City Hospital Campus, Nottingham University Hospitals, Nottingham, United Kingdom (Ellis)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elizabeth Hale","family":"Hammond","sequence":"additional","affiliation":[{"name":"Department of Pathology, Intermountain Healthcare and University of Utah School of Medicine, Salt Lake City (Hammond)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lebeau","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf, Institute of Pathology, Hamburg, Germany (Lebeau)"},{"name":"Private Group Practice for Pathology, L\u00fcbeck, Germany (Lebeau)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Y.","family":"Osamura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Nippon Koukan Hospital, Kawasaki, Japan (Osamura)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9derique","family":"Penault-Llorca","sequence":"additional","affiliation":[{"name":"Centre Jean Perrin, Universit\u00e9 Clermont Auvergne, INSERM, U1240 Imagerie Mol\u00e9culaire et Strat\u00e9gies Th\u00e9ranostiques, Clermont Ferrand, France (Penault-Llorca)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[{"name":"Department of Pathology, IIS-Hospital Universitario Fundacion Jimenez Diaz-CIBERONC, Madrid, Spain (Rojo)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Desai","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Basking Ridge, New Jersey (Desai, Moh)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Moh","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Basking Ridge, New Jersey (Desai, Moh)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Atkey","sequence":"additional","affiliation":[{"name":"Diaceutics plc, Dataworks at Kings Hall Life Sciences Park, Belfast, County Antrim, United Kingdom (Atkey)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Baenfer","sequence":"additional","affiliation":[{"name":"From the Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany (R\u00fcschoff, Penner, Baenfer, Schildhaus)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Scheel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Cologne, Cologne, Germany (Scheel)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"D\u2019Arrigo","sequence":"additional","affiliation":[{"name":"Poundbury Cancer Institute, Dorchester, United Kingdom (D\u2019Arrigo)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[{"name":"From the Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany (R\u00fcschoff, Penner, Baenfer, Schildhaus)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Pathology, IEO European Institute of Oncology IRCCS Milan, Italy (Viale)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"HER2-Low Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"issue":"10","key":"2025042419523233900_i1543-2165-149-5-431-b01","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/OP.21.00172","article-title":"Current and future management of HER2-positive metastatic breast cancer","volume":"17","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2025042419523233900_i1543-2165-149-5-431-b02","doi-asserted-by":"crossref","first-page":"676939","DOI":"10.3389\/fonc.2021.676939","article-title":"A companion diagnostic with significant clinical impact in treatment of breast and gastric cancer","volume":"11","author":"J\u00f8rgensen","year":"2021","journal-title":"Front Oncol"},{"key":"2025042419523233900_i1543-2165-149-5-431-b03","unstructured":"NordiQC\n          . HER2 IHC: assessment run B36 2023. https:\/\/www.nordiqc.org\/downloads\/assessments\/175_11.pdf. Accessed April 3, 2024."},{"issue":"11","key":"2025042419523233900_i1543-2165-149-5-431-b04","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b05","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"2025042419523233900_i1543-2165-149-5-431-b06","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"2025042419523233900_i1543-2165-149-5-431-b07","unstructured":"US Food and Drug Administration\n          . FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer. Published August 5, 2022. Accessed March 8, 2023."},{"key":"2025042419523233900_i1543-2165-149-5-431-b08","unstructured":"European Medicines Agency. Enhertu trastuzumab deruxtecan\n          . https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enhertu. Published December 15, 2022. Accessed June 5, 2024."},{"key":"2025042419523233900_i1543-2165-149-5-431-b09","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1309\/VE7862V2646BR6EX","article-title":"HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring","volume":"121","author":"Lal","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"2025042419523233900_i1543-2165-149-5-431-b10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00428-016-1940-y","article-title":"In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+\/Her2 amplified cases","volume":"469","author":"Giuliani","year":"2016","journal-title":"Virchows Archiv"},{"issue":"17","key":"2025042419523233900_i1543-2165-149-5-431-b11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"2025042419523233900_i1543-2165-149-5-431-b12","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1097\/MD.0000000000000645","article-title":"HER2 status determination: analyzing the problems to find the solutions","volume":"94","author":"Terrenato","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2025042419523233900_i1543-2165-149-5-431-b13","doi-asserted-by":"crossref","first-page":"151451","DOI":"10.1016\/j.anndiagpath.2019.151451","article-title":"HER2 immunohistochemistry inter-observer reproducibility in 205 cases of invasive breast carcinoma additionally tested by ISH","volume":"45","author":"Caster\u00e1","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"17","key":"2025042419523233900_i1543-2165-149-5-431-b14","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.ejca.2006.06.020","article-title":"High inter-observer agreement in immunohistochemical evaluation of HER-2\/neu expression in breast cancer: a multicentre GEFPICS study","volume":"42","author":"Lacroix-Triki","year":"2006","journal-title":"Eur J Cancer"},{"key":"2025042419523233900_i1543-2165-149-5-431-b15","volume-title":"Surveys and Anatomic Pathology Education Programs\u2014 Immunohistochemistry Tissue Microarray HER2-B 2019 Participant Survey","author":"College of American Pathologists","year":"2019"},{"issue":"4","key":"2025042419523233900_i1543-2165-149-5-431-b16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2021.7239","article-title":"Examination of low HER2 protein expression in breast cancer tissue","volume":"8","author":"Fernandez","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"2025042419523233900_i1543-2165-149-5-431-b17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"2025042419523233900_i1543-2165-149-5-431-b18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"2025042419523233900_i1543-2165-149-5-431-b19","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2021.39.15_suppl.1021","article-title":"Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2\/neu (4B5) assay","volume":"39","author":"Scott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025042419523233900_i1543-2165-149-5-431-b20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod Pathol"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13000-018-0696-x","article-title":"Physical basis of the \u2018magnification rule\u2019 for standardized immunohistochemical scoring of HER2 in breast and gastric cancer","volume":"13","author":"Scheel","year":"2018","journal-title":"Diagn Pathol"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13000-020-00953-9","article-title":"Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer","volume":"15","author":"Jasani","year":"2020","journal-title":"Diagn Pathol"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b23","first-page":"10","article-title":"ReCal OIR: ordinal, interval, and ratio intercoder reliability as a web service","volume":"8","author":"Freelon","year":"2013","journal-title":"Int J Internet Sci"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"issue":"3","key":"2025042419523233900_i1543-2165-149-5-431-b25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2025042419523233900_i1543-2165-149-5-431-b26","doi-asserted-by":"crossref","first-page":"151561","DOI":"10.1016\/j.anndiagpath.2020.151561","article-title":"Pathologists should probably forget about kappa. Percent agreement, diagnostic specificity and related metrics provide more clinically applicable measures of interobserver variability","volume":"47","author":"Marchevskya","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"2025042419523233900_i1543-2165-149-5-431-b27","unstructured":"R Core Team\n          . R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Version 4.2.1. https:\/\/www.r-project.org\/ and https:\/\/cran.r-project.org\/mirrors.html. Accessed July 17, 2024."},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2025042419523233900_i1543-2165-149-5-431-b29","volume-title":"Surveys and Anatomic Pathology Education Programs \u2013 Immunohistochemistry Tissue Microarray HER2-B 2021 Participant Survey","author":"College of American Pathologists","year":"2021"},{"issue":"4","key":"2025042419523233900_i1543-2165-149-5-431-b30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/modpathol.2017.171","article-title":"Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years","volume":"31","author":"Pfitzner","year":"2018","journal-title":"Mod Pathol"},{"issue":"5","key":"2025042419523233900_i1543-2165-149-5-431-b31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/134.5.751","article-title":"Proficiency testing performance in US laboratories: results reported to the Centers for Medicare & Medicaid Services, 1994 through 2006","volume":"134","author":"Howerton","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b32","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.modpat.2022.100032","article-title":"Multi-institutional assessment of pathologist scoring HER2 immunohistochemistry","volume":"36","author":"Robbins","year":"2023","journal-title":"Mod Pathol"},{"issue":"1","key":"2025042419523233900_i1543-2165-149-5-431-b33","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.modpat.2022.100009","article-title":"Interobserver variation in the assessment of immunohistochemistry expression levels in HER2-negative breast cancer: can we improve the identification of low levels of HER2 Expression by Adjusting the Criteria? An international interobserver study","volume":"36","author":"Baez-Navarro","year":"2023","journal-title":"Mod Pathol"},{"key":"2025042419523233900_i1543-2165-149-5-431-b34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.breast.2023.06.005","article-title":"Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the Republic of Ireland\u2014on behalf of the UK national coordinating committee for breast pathology","volume":"70","author":"Zaakouk","year":"2023","journal-title":"Breast"},{"key":"2025042419523233900_i1543-2165-149-5-431-b35","doi-asserted-by":"crossref","DOI":"10.1136\/jcp-2023-209055","article-title":"Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer","author":"Turashvili","year":"2023","journal-title":"J Clin Pathol"},{"issue":"5","key":"2025042419523233900_i1543-2165-149-5-431-b36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/aqac184","article-title":"Interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort","volume":"159","author":"Karakas","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2025042419523233900_i1543-2165-149-5-431-b37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","article-title":"Pour le GEFPICS. Mise \u00e0 jour 2021 des recommandations du GEFPICS pour l\u2018\u00e9valuation du statut HER2 dans les cancers infiltrants du sein en France [2021 update of the GEFPICS\u2019 recommendations for HER2 status assessment in invasive breast cancer in France]","volume":"41","author":"Franchet","year":"2021","journal-title":"Ann Pathol"},{"issue":"Suppl 2","key":"2025042419523233900_i1543-2165-149-5-431-b38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00292-022-01139-4","article-title":"New treatment options for metastatic HER2-low breast cancer: consequences for histopathological diagnosis","volume":"44","author":"Denkert","year":"2023","journal-title":"Pathologie (Heidelb"},{"issue":"4","key":"2025042419523233900_i1543-2165-149-5-431-b39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jcp-2022-208632","article-title":"UK recommendations for HER2 assessment in breast cancer: an update","volume":"76","author":"Rakha","year":"2023","journal-title":"J Clin Pathol"},{"issue":"2","key":"2025042419523233900_i1543-2165-149-5-431-b40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40139-018-0170-1","article-title":"A new paradigm for tissue diagnostics: tools and techniques to standardize tissue collection, transport, and fixation","volume":"6","author":"Bauer","year":"2018","journal-title":"Curr Pathobiol Rep"},{"issue":"2","key":"2025042419523233900_i1543-2165-149-5-431-b41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5858\/2008-132-211-NHPTRU","article-title":"National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures","volume":"132","author":"Vani","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2025042419523233900_i1543-2165-149-5-431-b42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/his.13333","article-title":"HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues","volume":"72","author":"Qaiser","year":"2018","journal-title":"Histopathology"},{"issue":"7","key":"2025042419523233900_i1543-2165-149-5-431-b43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/PAI.0000000000000930","article-title":"Quantitative image analysis for tissue biomarker use: a white paper from the Digital Pathology Association","volume":"29","author":"Lara","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"10","key":"2025042419523233900_i1543-2165-149-5-431-b44","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5858\/arpa.2018-0378-CP","article-title":"Quantitative image analysis of human epidermal growth factor receptor 2 immunohistochemistry for breast cancer: guideline from the College of American Pathologists","volume":"143","author":"Bui","year":"2019","journal-title":"Arch Pathol Lab Med"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/5\/431\/3509659\/i1543-2165-149-5-431.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/5\/431\/3509659\/i1543-2165-149-5-431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:39:48Z","timestamp":1764790788000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/5\/article-p431.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,8]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0052-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}